Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion.
Saved in:
| Title: | Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion. |
|---|---|
| Authors: | Kilic IB; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Weberova P; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., VanDyke D; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Sirova M; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Kubesova K; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Fabilane CS; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Program in Molecular Biophysics, Johns Hopkins University, Baltimore, Maryland, USA., Mazhara V; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Liu K; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Behalova K; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Ptacek B; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Rihova B; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Spangler JB; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Molecular Microbiology & Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Kovar M; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic makovar@biomed.cas.cz. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Aug 11; Vol. 13 (8). Date of Electronic Publication: 2025 Aug 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40789741 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kilic+IB%22">Kilic IB</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Weberova+P%22">Weberova P</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22VanDyke+D%22">VanDyke D</searchLink>; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Sirova+M%22">Sirova M</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Kubesova+K%22">Kubesova K</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Fabilane+CS%22">Fabilane CS</searchLink>; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Program in Molecular Biophysics, Johns Hopkins University, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Mazhara+V%22">Mazhara V</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Liu+K%22">Liu K</searchLink>; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Behalova+K%22">Behalova K</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Ptacek+B%22">Ptacek B</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Rihova+B%22">Rihova B</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Spangler+JB%22">Spangler JB</searchLink>; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Molecular Microbiology & Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Kovar+M%22">Kovar M</searchLink>; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic makovar@biomed.cas.cz. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2025 Aug 11; Vol. 13 (8). <i>Date of Electronic Publication: </i>2025 Aug 11. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40789741 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2024-010465 Languages: – Code: eng Text: English Titles: – TitleFull: Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kilic IB – PersonEntity: Name: NameFull: Weberova P – PersonEntity: Name: NameFull: VanDyke D – PersonEntity: Name: NameFull: Sirova M – PersonEntity: Name: NameFull: Kubesova K – PersonEntity: Name: NameFull: Fabilane CS – PersonEntity: Name: NameFull: Mazhara V – PersonEntity: Name: NameFull: Liu K – PersonEntity: Name: NameFull: Behalova K – PersonEntity: Name: NameFull: Ptacek B – PersonEntity: Name: NameFull: Rihova B – PersonEntity: Name: NameFull: Spangler JB – PersonEntity: Name: NameFull: Kovar M IsPartOfRelationships: – BibEntity: Dates: – D: 11 M: 08 Text: 2025 Aug 11 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 13 – Type: issue Value: 8 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
